Industry News

Pharmaceutical Industry News

A handful of pharmas and…

February 27th, 2026|Fierce Pharma|

A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation for a long-lasting awareness push.

While the FDA has flip-flopped on…

February 27th, 2026|Fierce Pharma|

While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with a positive recommendation from the CHMP.

Two years and five indications…

February 27th, 2026|Fierce Pharma|

Two years and five indications later, UCB's immunology blockbuster Bimzelx is halfway to the company's initial goal of at least 4 billion euros ($4.4 billion) in peak sales.

As one long-running feud over the…

February 27th, 2026|Fierce Pharma|

As one long-running feud over the controversial generic drug carve-out known as “skinny” labeling comes to a close, the U.S.’ top lawyer is urging the Supreme Court to reverse a recent decision on another, arguing

China assets have outgrown a…

February 27th, 2026|Fierce Pharma|

China assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, Evaluate said. Daiichi Sankyo named former Novartis exec John Tsai, M.D., as its new R&D head.

Fierce Pharma’s Angus Liu speaks…

February 27th, 2026|Fierce Pharma|

Fierce Pharma's Angus Liu speaks with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former FDA oncology division director, about a recent article from agency officials outlining how the FDA plans

In this webinar, which is a…

February 26th, 2026|Fierce Pharma|

In this webinar, which is a rebroadcast from the 2025 PODD Conference, business development and technology assessment professionals actively involved in the scouting and evaluating of novel delivery technologies, discuss the constantly evolving topic of partnering. 

This webinar addresses how…

February 26th, 2026|Fierce Pharma|

This webinar addresses how pharmaceutical organizations are expanding their clinical trial operations globally to support evolving portfolios and react to geopolitics.

Patients and caregivers share…

February 26th, 2026|Fierce Pharma|

Patients and caregivers share their perspectives on their clinical trial experiences to help industry with future trial optimization and accessibility.

Less than six months after…

February 26th, 2026|Fierce Pharma|

Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly widened its reach into the first-line setting

Following an unexpected delay of…

February 26th, 2026|Fierce Pharma|

Following an unexpected delay of the CDC vaccine panel's February meeting, the Advisory Committee on Immunization Practices (ACIP) has selected dates next month to convene and discuss, among other matters, COVID-19 vaccine safety.

Already on a roll with its…

February 26th, 2026|Fierce Pharma|

Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular myasthenia gravis.

Sarepta Therapeutics CEO Doug…

February 26th, 2026|Fierce Pharma|

Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ironic twist of fate” involving the health of his family.

Viatris’ three-year reorganization…

February 26th, 2026|Fierce Pharma|

Viatris' three-year reorganization will affect staffers in a range of functions including the company's commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.

GSK’s every-two-month injection…

February 25th, 2026|Fierce Pharma|

GSK's every-two-month injection kept adolescents with HIV virologically suppressed at 96 weeks, GSK's ViiV presented at the recent Conference on Retroviruses and Opportunistic Infections.

The treatment landscape for clear…

February 25th, 2026|Fierce Pharma|

The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor could hinder these Welireg regimens

AI is now routine in how people…

February 25th, 2026|Fierce Pharma|

AI is now routine in how people search and process information, with users relying on systems interpreting intent and delivering direct responses, especially in healthcare.